SmartTRAK's Elise Wolf, Vice President and General Manager of Orthopedics, Digital and Quality, along with Beth Roach, Director, Data Strategy, will be discussing new trends in Ambulatory Surgical Centers (ASC) and effective targeting strategies at the 2023 Musculoskeletal New Ventures Conference (MNVC) on Nov 14-15 at the FedEx Institute of Technology in Memphis, TN. They will also delve into a detailed case study on ASC builds. Their presentation is titled "Targeting the ASC: Essential Knowledge for Orthopedic Companies." Make sure you don’t miss out on Elise and Beth's expert insights!
3 min read
The Future of Venous and Lymphatic Medicine: SmartTRAK at UIP 2023
At the 20th World Congress of the International Union of Phlebology, SmartTRAK identifies market developments that will impact the treatment of venous and lymphatic diseases now and in the future.
The American Vein and Lymphatic Society recently hosted the 20th World Congress of the International Union of Phlebology (UIP 2023) in Miami Beach, FL. The Congress drew clinicians from around the world to discuss the latest advances in venous and lymphatic medicine. While the Congress covered many interesting topics, SmartTRAK noted market developments that will impact the treatment of venous and lymphatic diseases now and in the future. In this article, SmartTRAK explores the impact that the Centers for Medicare and Medicaid Services (CMS) reimbursement cuts are having on physicians treating venous and lymphatic diseases, examines how clinicians and industry are responding to the proposed Medicare coverage of lymphedema treatment items and evaluates what’s on the horizon for emerging technologies.
This downloadable article, discussing the market developments that will impact the treatment of venous and lymphatic diseases now and in the future, delves into many compelling topics, including:
Physician Payment Cuts
The American Medical Association reported that between 2001 and 2023, the cost of operating a medical practice increased by 47%, while physician payment rates increased by only 9%. When adjusted for inflation, the rates have gone down by 26%. Dr. John Blebea, Vascular Surgeon and Clinical Professor of Surgery at Central Michigan University, underscored this point with a presentation titled “The Effect of Medicare Physician Reimbursement Cuts on Office-Based Practices.” Dr. Blebea noted that ...
New Medicare Coverage of Lymphedema Treatment Items
Medicare currently provides Durable Medical Equipment (DME) coverage or authorizes payment for certain compression items when used to treat venous stasis ulcers. However, Medicare does not provide coverage for many of the same items when they are used to treat lymphedema. This dynamic provides a great case study of the effectiveness of advocacy in calling for ...
Emerging Technologies
If innovation fuels growth in the med tech industry, then the number of sessions on emerging technologies at UIP 2023 should mean that the future is bright for venous and lymphatic medicine. Dr. Steve Elias, Director, Center for Vein Disease, Englewood Health Network, hosted several sessions on emerging innovations in thrombectomy, sclerotherapy, artificial intelligence (AI)-guided imaging, intravascular ultrasound and compression therapy. SmartTRAK has covered the Compression Therapy Market since 2015 and has watched ...
To download and read the complete article about The Future of Venous and Lymphatic Medicine by Terry Hayslett, SmartTRAK Senior Analyst, Advanced Wound Care, just click the button below.
3 min read
Anika's Expanding Shoulder Preservation Solutions
Anika’s President and CEO Cheryl Blanchard, Ph.D., discusses the Company’s expanding portfolio of shoulder preservation solutions
Anika Therapeutics entered the Reverse Shoulder Market this year with the US market release of the RevoMotion Reverse Shoulder
Arthroplasty System, expanding their complement of products for shoulder joint preservation and replacement. This new offering allows the Company to compete in the rapidly growing US Market for Reverse Shoulders.
Lisa Mahan,
SmartTRAK
Senior Analyst Total Joints & Extremities, talked with Cheryl Blanchard, PhD, President and CEO of Anika, to discuss the launch of RevoMotion, along with the X-Twist
Fixation System, Integrity
Patch System, Cingal
next generation OA injectable and Tactoset
Injectable Bone Substitute.
The Interview
SmartTRAK: RevoMotion has been out almost nine months now in limited release and you just went to full market release. Congratulations. How is that going?
Cheryl Blanchard: Thank you! Anika announced the full market release of the RevoMotion Reverse Shoulder Arthroplasty System (RSA) during the 2023 Orthopaedic Summit (OSET) Annual Meeting September 20-23 in Boston, MA and the response has been overwhelmingly positive.
We began the limited launch in January 2023 and have performed over 100 cases since then. The feedback we received and the response during the limited market release was impressive as some of the first patients in have already returned to their surgeons and asked for the same implant to be placed in their other shoulder. To have patients far enough into recovery to want the RevoMotion RSA in their other shoulder says a lot about the system and its future success. The limited release allowed us to collect feedback to better optimize the instrumentation and surgical technique for the full market release as well. Though we finished gathering feedback months ago, manufacturing instrument sets and system components takes time. That brought us right to our full market release during OSET in September.
We know that the reverse shoulder market is a crowded space. Given that probably 80% of the market is reverse shoulders, for Anika we knew we had something incredible to offer clinicians and patients based on the historic Arthrosurface design philosophies focused on bone sparing, motion preservation and anatomic design features. We also knew that with the data-backed and trusted OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System, it would be difficult to penetrate the full shoulder arthroplasty market without having a reverse option.
Additionally, there is a big shift of a lot of these products and procedures into the ASC setting. We will possibly see even more products coming into the ASC when CMS changes how they reimburse and we realized that there was a real opportunity to provide optimized instrument trays that would reduce the operating room footprint. RevoMotion has a two-tray instrumentation system that is very streamlined. The surgical technique is also very streamlined. We're hearing great feedback on it and we're excited to be in full market release coming into the fourth quarter.
That's wonderful. You mentioned the instrument trays and some of the design. If there was one thing that differentiates RevoMotion from other reverse shoulders on the market, what would you say that is?
CB:We believe and continue to hear feedback from surgeon users that having the smallest threaded glenoid base plate on the market is one of the biggest differentiators. Personally, I didn't understand the true significance of that until I started to speak directly with surgeons who had used the system. Listening to real-time feedback and observing in the OR, you realize it's a major benefit as it provides...
To download and read the complete transcript of the interview with Anika’s President & CEO Cheryl Blanchard conducted by Lisa Mahan, VP Product Development & IT, Sr. Analyst TJ&E, just click the button below. 
Topics:
Orthopedics
Top Story
Continue Reading
4 min read
SmartTRAK Announces Software Advancements & Launches Insights Reports for Emerging Orthopedic/Spine and Wound Medtech Markets
New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.
SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the release of enhanced software products and strategic reports available for purchase in Q4 to help clients position themselves for growth in 2024 and beyond.
Powered by industry experts and data analysts, SmartTRAK's Insights-as-a-Service platform is the Medtech industry's only "all-in-one" solution that delivers market insights and business intelligence via an intuitive SaaS platform. Designed to reduce the redundancies in market research, SmartTRAK compiles and curates insights from hundreds of disparate information sources into its highly valued SmartTRAK Daily Updates, comprehensive market overviews and simple-to-use tools and dashboards for market, product and financial analysis.
1 min read
Trends Potentially Impacting the Total Joints Market: A Flash Report
SmartTRAK takes a quick look at recent trends that may influence the Total Joints Market in the near and long term
Wall Street Analysts recently called out two trends specifically that could influence the Total Joints Market. One trend, the strengthening of the US dollar, is likely to impact the global market in 2024. Another trend is the increased prescribing of GLP-1 drugs, such as Ozempic, Wegovy, Byetta and Mounjaro, medications first used to treat Type 2 diabetes, as a treatment for obesity. This has the potential to impact the market down the road. In this downloadable article, SmartTRAK maps out the potential impact of these trends.
To download and read the complete article by SmartTRAK's Lisa Mahan, Product Development & IT, Sr. Analyst TJ&E, just click the button below. 
3 min read
Medtronic: Expanding Access to Neurovascular Interventions
Medtronic Neurovascular President Dan Volz discusses expanding patient access to neurovascular therapies through innovation and globalization in an interview with SmartTRAK.
Medtronic Neurovascular President Dan Volz discusses innovation, globalization and the Company’s plans to double the number of neurovascular patients treated annually in three years in an interview with SmartTRAK. Volz said the Company is driving growth in Neurovascular through innovative business models and strategic investments in remote connectivity and the Medtronic Neurovascular Co-Lab Platform, a novel incubator designed to accelerate innovation in stroke care and treatment. To find out more about the Company and its latest innovations, click on the video to listen to the full interview (27:30 min). To download a transcript of the complete interview, just click the button below.
Anne Staylor here with SmartTRAK. Today I have the pleasure of interviewing Dan Volz, president of Medtronic Neurovascular. Dan, thank you for speaking with me today.
Dan Volz: It's my pleasure. It's good to talk to you.
I haven't talked to you for a while and I was hoping to catch up with you at SNIS when it was here in San Diego. Now that we are talking, let's just start broadly and talk from your perspective, what's important for us to know about Medtronic Neurovascular and what are your top priorities for fiscal year 2024?
DV: It's good to see you and I'm sorry that I missed you down in San Diego. That was a pretty quick up and back for me, but for us obviously it's about the patients and we had a pretty important milestone in 2022. In a 12-month period we helped treat 250,000 people, so that was a great celebration for us as a business. But I think even more importantly, it kicked off our strategic planning process to double that number in three years. And so everything that we do is centered on how do we drive toward that number? And there's a lot that goes into that, but it starts with obviously innovation and how are we innovating in our portfolio? What are we doing organically and what are we looking at inorganically to drive toward that number? And you know these statistics as well as anyone, there's 15 million strokes and we only treat five to 600,000 of them a year ...
To download and read the transcript of the complete interview with Dan Volz, president of Medtronic Neurovascular, by SmartTRAK's Anne Staylor, Executive Editor, VP & GM of Neuro Therapies, just clickthe button below. 
2 min read
Kerecis and the Road to Success: An Interview with CEO Fertram Sigurjonsson
Fertram Sigurjonsson, CEO of Kerecis, discusses the recent acquisition, how the Company has evolved over the last decade and key milestones along its “Road to Success” in an interview with SmartTRAK.
Topics:
Wound Care
Continue Reading
2 min read
EPUAP 2023 – Prevention Proves Better than Cure for European Dressing Companies
Increasing acceptance of diagnostics, as well as the repositioning of existing technologies, could help drive growth in European wound care.
Pressure injuries are globally accepted as a major healthcare challenge. SmartTRAK estimates there were 10.2MM pressure ulcers in Europe in 2022, with 4.0MM being stage III or IV. At the 23rd European Pressure Ulcer Advisory Panel (EPUAP) meeting recently held in Leeds, UK, the main focus of the meeting was on diagnosing and treating the more challenging stage III/IV pressure ulcers. In this downloadable article SmartTRAK explores how diagnostics continues to be a major driver of innovation within the space and how companies and products previously focused on treatment are now firmly positioning themselves within the prevention space, where SmartTRAK will soon offer brand-new insights.
Among the many topics covered in the article are:
- Diagnostics
The perception of diagnostic tools within European wound care appears to be evolving. Previously, they had been viewed as aspirational but unaffordable luxuries, but are now becoming ... - Wound Treatments
There was a distinct lack of new technologies for the treatment of pressure injuries on display in the exhibition, with existing dressings and negative pressure wound therapy (NPWT) being the main solutions on stands. New treatment solutions were ... - Dressings for Pressure Injury Prevention
Historically, clinicians have used dressings designed for managing open wounds as a method of pressure injury prevention. In the last decade, more and more dressings companies have been recognizing the possibilities offered within this market. Published evidence suggests ...
To download and read the complete "Prevention Proves Better than Cure for European Dressing Companies" perspective article by SmartTRAK's Aniko Szeker, Sr Analyst, Wound and Kris Finn, Sr Analyst, Wound, please click the button below.
2 min read
AWC Summit 2023: Big Deals and Bright Ideas Drive Excitement
SmartTRAK joined industry colleagues in Boston to explore new technologies at an exciting time in wound care.
SmartTRAK
forecasts
that the WW Advanced Wound Care (AWC) market will grow at a five-year CAGR of +5.3%. The
acquisition
of Kerecis
by Coloplast
highlights the value of successful products within the market. In Boston, MA, the week following the announcement of the Kerecis deal, stakeholders, including manufacturers and investors met at the
Advanced Wound Care Summit
(AWC Summit), an industry-led forum featuring insights from leading experts on the latest trends and innovations in wound care, with a focus on earlier-stage products and technologies. In this downloadable article,
SmartTRAK
provides an overview of the meeting and highlights companies that participated in the Innovation Showcase, a competition that features the most cutting-edge products or technologies. Also featured is
SmartTRAK’s interview with Suzanne Moloney, Founder and CEO at HidraMed Solutions, the company that won the showcase.
In this interview
,
Ms Maloney discusses HS and the Company’s journey to bring this technology to market. Click the video below to see the interview. A transcript of the interview is also provided in the
article.
The Advanced Wound Care Summit EU 2024
The next AWC Summit will be the European edition and will take place in London, UK on the 28th and 29th of November. SmartTRAK will be in attendance and will be presenting the latest insights within wound care. More information on the event is available here.
Topics:
Wound Care
Continue Reading
3 min read
SNIS 2023: New Frontiers in Stroke Care: An Interview with J Mocco, MD
SNIS President J Mocco, MD, discusses emerging technologies and new frontiers in neurointervention in an interview with SmartTRAK.
J Mocco, MD, President of the Society of Neurointerventional Surgery (SNIS), discusses the latest research and innovation in stroke care in an interview with SmartTRAK at the 20thAnnual Meeting of the SNIS recently held in San Diego, CA. To find out more regarding important research, emerging technologies and new frontiers in stroke care, listen to the following video. (27:12 min). A complete transcript of the interview can be downloaded below.
SmartTRAK: Hi, this is Anne Staylor with SmartTRAK. Today I'm covering the Society of Neurointerventional Surgery annual meeting here in San Diego, and I have the pleasure of speaking to J Mocco, MD, president of the SNIS. Dr. Mocco, thank you for talking with me today.
J Mocco, MD: Thank you very much for having me.
Well, this year I felt a lot of energy and vibrancy at the meeting, particularly when I walked into the exhibit hall, which is nice after some of the years we've had with COVID. One of the things I wanted to ask you is what are some of the exciting research studies at SNIS this year? Maybe you could just highlight some of the key research that is presented here at the meeting.
JM: Absolutely. I have to say this year was truly spectacular. The depth and breadth of new and exciting research and reports on technology and studies. This year we saw presentations on completely new technologies to treat brain aneurysms, multiple leap forwards in technologies to better remove clots from brains and cure people with stroke. Had very robust discussions on systems of care and how best to evaluate stroke patients. Is the current standard adequate? Should we have different methods of evaluating patient success? They're just examples of the really amazing things that are happening in this space in general, and particularly ...
To download the complete transcript of the interview with J Mocco, MD, President of SNIS, conducted by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies, just click the button below.
Topics:
Neuro Therapies
Continue Reading
